Aevi Genomic Medicine Inc logo

GNMX - Aevi Genomic Medicine Inc Share Price

$0.166 -0.0  -10.3%

Last Trade - 03/02/20

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 6339
Bullish
Bearish
Unlock GNMX Revenue
Momentum
Relative Strength (%)
1m -10.7%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 2019E 2020E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2019, Aevi Genomic Medicine Inc revenues was not reported. Net loss decreased 48% to $12.5M. Lower net loss reflects Research and development expenses - Bla decrease of 55% to $7.4M (expense), Other General & Administration expense decrease of 27% to $4M (expense), Stock-based Compensation in SGA decrease of 52% to $652K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

GNMX Revenue Unlock GNMX Revenue

Net Income

GNMX Net Income Unlock GNMX Revenue

Normalised EPS

GNMX Normalised EPS Unlock GNMX Revenue

PE Ratio Range

GNMX PE Ratio Range Unlock GNMX Revenue

Dividend Yield Range

GNMX Dividend Yield Range Unlock GNMX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
GNMX EPS Forecasts Unlock GNMX Revenue
Profile Summary

Aevi Genomic Medicine, Inc., formerly Medgenics, Inc., is focused on genomic medicine. The Company is engaged in unlocking the potential of genomic medicine to translate genetic discoveries into therapies. The Company is engaged in developing therapies for children and adults with pediatric onset life altering diseases. The Company's product candidates include AEVI-001 and AEVI-002. The Company's research and development efforts leverage an internal genomics platform and a collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). .

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated January 27, 2000
Public Since December 4, 2007
No. of Shareholders: n/a
No. of Employees: 14
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NASDAQ Capital Market
Shares in Issue 77,713,782
Free Float (0.0%)
Eligible for
ISAs
SIPPs
GNMX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for GNMX
Upcoming Events for GNMX
Frequently Asked Questions for Aevi Genomic Medicine Inc
What is the Aevi Genomic Medicine Inc share price?

As of 03/02/20, shares in Aevi Genomic Medicine Inc are trading at $0.166, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Aevi Genomic Medicine Inc share price performed this year?

Shares in Aevi Genomic Medicine Inc are currently trading at $0.166 and the price has moved by -26.88% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Aevi Genomic Medicine Inc price has moved by -30.09% over the past year.

What are the analyst and broker recommendations for Aevi Genomic Medicine Inc?

Of the analysts with advisory recommendations for Aevi Genomic Medicine Inc, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Aevi Genomic Medicine Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Aevi Genomic Medicine Inc next release its financial results?

Aevi Genomic Medicine Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-09-30
What is the Aevi Genomic Medicine Inc dividend yield?

Aevi Genomic Medicine Inc does not currently pay a dividend.

Does Aevi Genomic Medicine Inc pay a dividend?

Aevi Genomic Medicine Inc does not currently pay a dividend.

When does Aevi Genomic Medicine Inc next pay dividends?

Aevi Genomic Medicine Inc does not currently pay a dividend.

How do I buy Aevi Genomic Medicine Inc shares?

To buy shares in Aevi Genomic Medicine Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Aevi Genomic Medicine Inc?

Shares in Aevi Genomic Medicine Inc are currently trading at $0.166, giving the company a market capitalisation of £n/a.

Where are Aevi Genomic Medicine Inc shares listed? Where are Aevi Genomic Medicine Inc shares listed?

Here are the trading details for Aevi Genomic Medicine Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: GNMX
What kind of share is Aevi Genomic Medicine Inc?

We were not able to load our ranking data for Aevi Genomic Medicine Inc

Is there a Aevi Genomic Medicine Inc share price forecast 2020?

We were not able to load any forecast data for Aevi Genomic Medicine Inc.

How can I tell whether the Aevi Genomic Medicine Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aevi Genomic Medicine Inc. Over the past six months, the relative strength of its shares against the market has been -26.36%. At the current price of $0.166, shares in Aevi Genomic Medicine Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Aevi Genomic Medicine Inc PE Ratio?

We were not able to find PE ratio data for Aevi Genomic Medicine Inc.

Who are the key directors of Aevi Genomic Medicine Inc?

We were unable to find the directors for Aevi Genomic Medicine Inc.

Who are the major shareholders of Aevi Genomic Medicine Inc?

Here are the top five shareholders of Aevi Genomic Medicine Inc based on the size of their shareholding:

Children's Hospital of Philadelphia Foundation Corporation
Percentage owned: 23.71% (18.4m shares)
Harper (Philip R) Individual Investor
Percentage owned: 6.34% (4.92m shares)
Renaissance Technologies LLC Hedge Fund
Percentage owned: 3.08% (2.39m shares)
Cola (Michael F) Individual Investor
Percentage owned: 2.92% (2.27m shares)
Neil Garry Arthur Individual Investor
Percentage owned: 2.78% (2.16m shares)
Similar to GNMX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.